Patients receiving RINVOQ also had greater improvements in physical function at week 12, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). Patients in the 15 mg and 30 mg RINVOQ groups reported a -0.42 and -0.47 change from baseline in HAQ-DI score, respectively, compared to -0.14 on placebo (p<0.0001). RINVOQ also showed improvement in skin symptoms at week 16, with 63 percent and 62 percent of patients receiving 15 mg and 30 mg of RINVOQ achieving a 75 percent improvement in the Psoriasis Area Severity Index (PASI 75), respectively, compared to 21 percent on placebo (p<0.0001). Minimal disease activity (MDA) at week 24 was achieved in 37 percent and 45 percent of 15 mg and 30 mg RINVOQ-treated patients, respectively, versus 12 percent of the placebo group (p<0.0001).
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.